---
figid: PMC7481617__tlcr-09-04-1599-f1
figlink: pmc/articles/PMC7481617/figure/f1/
number: Figure 1
caption: 'Estrogen receptor (ER) and pan-HER signaling inhibition has synergistic
  activity and leads to gene expression changes associated with good prognosis in
  non-small cell lung cancer (NSCLC). In the discussed report, the authors demonstrate
  that fulvestrant and dacomitinib, a pan-HER family inhibitor, has synergistic activity
  in NSCLC including tumors without effective therapies such as those with KRAS mutations.
  Interestingly, the authors demonstrate that single-agent fulvestrant or dacomitinib
  led to upregulation of the other pathway. ER upregulates HER signaling through increasing
  expression of HER ligands, while it remains largely unclear how ER expression is
  upregulated by HER signaling. This reciprocal upregulation was prevented with combination
  therapy. The activity of this combination was associated with downregulation of
  the activator protein-1 (AP-1) and cAMP response element binding protein (CREB)
  transcription factors and reversal of a seven-gene signature previously implicated
  in poor prognosis in NSCLC. Future studies are needed to determine whether there
  are additional molecular targets of this combination, which genes/pathways are required
  for activity of the combination, and the mechanisms by which this combination leads
  to synergistic activity in NSCLC. A portion of this figure was created using modified
  Servier Medical Art templates, which are under a Creative Commons Attribution 3.0
  Unported License: https://smart.servier.com. E, estrogen; ERE, estrogen response
  element; TRE, TPA response element; CRE, cAMP response element; EMT, epithelial-mesenchymal
  transition.'
pmcid: PMC7481617
papertitle: Hormone gene signature guides a novel therapeutic opportunity to improve
  sensitivity to HER family inhibition in lung cancer.
reftext: Zachary A. Yochum, et al. Transl Lung Cancer Res. 2020 Aug;9(4):1599-1605.
pmc_ranked_result_index: '21630'
pathway_score: 0.9760397
filename: tlcr-09-04-1599-f1.jpg
figtitle: Estrogen receptor (ER) and pan-HER signaling inhibition has synergistic
  activity and leads to gene expression changes associated with good prognosis in
  non-small cell lung cancer (NSCLC)
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7481617__tlcr-09-04-1599-f1.html
  '@type': Dataset
  description: 'Estrogen receptor (ER) and pan-HER signaling inhibition has synergistic
    activity and leads to gene expression changes associated with good prognosis in
    non-small cell lung cancer (NSCLC). In the discussed report, the authors demonstrate
    that fulvestrant and dacomitinib, a pan-HER family inhibitor, has synergistic
    activity in NSCLC including tumors without effective therapies such as those with
    KRAS mutations. Interestingly, the authors demonstrate that single-agent fulvestrant
    or dacomitinib led to upregulation of the other pathway. ER upregulates HER signaling
    through increasing expression of HER ligands, while it remains largely unclear
    how ER expression is upregulated by HER signaling. This reciprocal upregulation
    was prevented with combination therapy. The activity of this combination was associated
    with downregulation of the activator protein-1 (AP-1) and cAMP response element
    binding protein (CREB) transcription factors and reversal of a seven-gene signature
    previously implicated in poor prognosis in NSCLC. Future studies are needed to
    determine whether there are additional molecular targets of this combination,
    which genes/pathways are required for activity of the combination, and the mechanisms
    by which this combination leads to synergistic activity in NSCLC. A portion of
    this figure was created using modified Servier Medical Art templates, which are
    under a Creative Commons Attribution 3.0 Unported License: https://smart.servier.com.
    E, estrogen; ERE, estrogen response element; TRE, TPA response element; CRE, cAMP
    response element; EMT, epithelial-mesenchymal transition.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AREG
  - EGF
  - ERBB2
  - ERBB3
  - EGFR
  - HRAS
  - KRAS
  - NRAS
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - MAPK3
  - MAPK1
  - AKT2
  - AKT3
  - AKT1
  - MYC
  - CXXC5
  - PGR
  - JUN
  - FOS
  - ATF2
  - CREB5
  - CREB3
  - CREB3L3
  - ATF1
  - CREB1
  - CREM
  - CREB3L2
  - CREB3L1
  - CREB3L4
  - MIA
  - GRB7
  - FOSB
  - FOSL2
  - JUNB
  - FOSL1
  - JUND
  - FGFR4
  - FGFRL1
  - FGFR1
  - FGFR3
  - FGFR2
  - FOXC1
  - TREH
  - ATP
  - Dacomitinib
genes:
- word: AREG
  symbol: AREG
  source: hgnc_symbol
  hgnc_symbol: AREG
  entrez: '374'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: HER2
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER3/HER2
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER3/HER2
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: HER2/EGFR
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER2/EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: c-MYC
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: CXXC5
  symbol: CXXC5
  source: hgnc_symbol
  hgnc_symbol: CXXC5
  entrez: '51523'
- word: PgR
  symbol: PGR
  source: hgnc_symbol
  hgnc_symbol: PGR
  entrez: '5241'
- word: Jun
  symbol: JUN
  source: hgnc_symbol
  hgnc_symbol: JUN
  entrez: '3725'
- word: Fos
  symbol: FOS
  source: hgnc_symbol
  hgnc_symbol: FOS
  entrez: '2353'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: ATF2
  entrez: '1386'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB5
  entrez: '9586'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB3
  entrez: '10488'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB3L3
  entrez: '84699'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: ATF1
  entrez: '466'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB1
  entrez: '1385'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREM
  entrez: '1390'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB3L2
  entrez: '64764'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB3L1
  entrez: '90993'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB3L4
  entrez: '148327'
- word: MIA
  symbol: MIA
  source: hgnc_symbol
  hgnc_symbol: MIA
  entrez: '8190'
- word: Grb-7
  symbol: GRB7
  source: hgnc_symbol
  hgnc_symbol: GRB7
  entrez: '2886'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOS
  entrez: '2353'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSB
  entrez: '2354'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSL2
  entrez: '2355'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUN
  entrez: '3725'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUNB
  entrez: '3726'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSL1
  entrez: '8061'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUND
  entrez: '3727'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: FOXC1
  symbol: FOXC1
  source: hgnc_symbol
  hgnc_symbol: FOXC1
  entrez: '2296'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: ATF2
  entrez: '1386'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB5
  entrez: '9586'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB3
  entrez: '10488'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB3L3
  entrez: '84699'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: ATF1
  entrez: '466'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB1
  entrez: '1385'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREM
  entrez: '1390'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB3L2
  entrez: '64764'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB3L1
  entrez: '90993'
- word: CREB
  symbol: CREB
  source: bioentities_symbol
  hgnc_symbol: CREB3L4
  entrez: '148327'
- word: Fos
  symbol: FOS
  source: hgnc_symbol
  hgnc_symbol: FOS
  entrez: '2353'
- word: Jun
  symbol: JUN
  source: hgnc_symbol
  hgnc_symbol: JUN
  entrez: '3725'
- word: Fos
  symbol: FOS
  source: hgnc_symbol
  hgnc_symbol: FOS
  entrez: '2353'
- word: Jun
  symbol: JUN
  source: hgnc_symbol
  hgnc_symbol: JUN
  entrez: '3725'
- word: TRE
  symbol: TRE
  source: hgnc_alias_symbol
  hgnc_symbol: TREH
  entrez: '11181'
- word: TRE
  symbol: TRE
  source: hgnc_alias_symbol
  hgnc_symbol: TREH
  entrez: '11181'
chemicals:
- word: ATP
  source: MESH
  identifier: D000255
- word: Dacomitinib
  source: MESH
  identifier: C525726
diseases: []
---
